UA71839C2 - Фармацевтическая композиция - Google Patents
Фармацевтическая композиция Download PDFInfo
- Publication number
- UA71839C2 UA71839C2 UA20031213128A UA20031213128A UA71839C2 UA 71839 C2 UA71839 C2 UA 71839C2 UA 20031213128 A UA20031213128 A UA 20031213128A UA 20031213128 A UA20031213128 A UA 20031213128A UA 71839 C2 UA71839 C2 UA 71839C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pharmaceutical composition
- glycine
- injections
- hydrochloride
- articaine
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 22
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims abstract description 19
- 229930182837 (R)-adrenaline Natural products 0.000 claims abstract description 18
- 229960005139 epinephrine Drugs 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 14
- 239000008215 water for injection Substances 0.000 claims abstract description 14
- 229940001584 sodium metabisulfite Drugs 0.000 claims abstract description 13
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- 230000001105 regulatory effect Effects 0.000 claims abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 29
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims description 20
- 239000004471 Glycine Substances 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 229960003831 articaine Drugs 0.000 claims description 12
- 229960002279 articaine hydrochloride Drugs 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 229960002449 glycine Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 230000003444 anaesthetic effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229940037001 sodium edetate Drugs 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000005526 vasoconstrictor agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- GDWDBGSWGNEMGJ-UHFFFAOYSA-N hydron;methyl 4-methyl-3-[2-(propylamino)propanoylamino]thiophene-2-carboxylate;chloride Chemical compound Cl.CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC GDWDBGSWGNEMGJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- YLXIPWWIOISBDD-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-NDAAPVSOSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- WNPNNLQNNJQYFA-YIDNRZKSSA-N 4-[(1r)-2-amino-1-hydroxyethyl]benzene-1,2-diol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.NC[C@H](O)C1=CC=C(O)C(O)=C1 WNPNNLQNNJQYFA-YIDNRZKSSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000699696 Meriones Species 0.000 description 1
- OBUCKZOJADTQNC-UHFFFAOYSA-M S(=O)(=O)([O-])S(=O)O.S(=O)(O)OS(=O)O.[Na+] Chemical compound S(=O)(=O)([O-])S(=O)O.S(=O)(O)OS(=O)O.[Na+] OBUCKZOJADTQNC-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- KAQHZJVQFBJKCK-UHFFFAOYSA-L potassium pyrosulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OS([O-])(=O)=O KAQHZJVQFBJKCK-UHFFFAOYSA-L 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к фармацевтической промышленности, в частности фармацевтической композиции на основе артикаина и эпинефрина, которая содержит такие вспомогательные вещества, как метабисульфит натрия, натрия хлорид, вещество, регулирующее рН, воду для инъекций и глицин.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20031213128A UA71839C2 (ru) | 2003-12-30 | 2003-12-30 | Фармацевтическая композиция |
| RU2004104191/15A RU2261092C1 (ru) | 2003-12-30 | 2004-02-16 | Фармацевтическая композиция, обладающая анестезирующей активностью |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20031213128A UA71839C2 (ru) | 2003-12-30 | 2003-12-30 | Фармацевтическая композиция |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| UA71839A UA71839A (en) | 2004-12-15 |
| UA71839C2 true UA71839C2 (ru) | 2007-06-25 |
Family
ID=34513787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20031213128A UA71839C2 (ru) | 2003-12-30 | 2003-12-30 | Фармацевтическая композиция |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2261092C1 (ru) |
| UA (1) | UA71839C2 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1011074A2 (pt) | 2009-06-04 | 2016-04-12 | Alk Ag | composição estabilizada que compreende pelo menos um composto adrenérgico |
-
2003
- 2003-12-30 UA UA20031213128A patent/UA71839C2/ru unknown
-
2004
- 2004-02-16 RU RU2004104191/15A patent/RU2261092C1/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2261092C1 (ru) | 2005-09-27 |
| RU2004104191A (ru) | 2005-07-27 |
| UA71839A (en) | 2004-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008727A (zh) | 一种提高川芎嗪药物注射制剂稳定性的注射用药物组合物及其制备方法 | |
| CZ300614B6 (cs) | Oftalmologická kompozice obsahující ketotifen | |
| EP1124567B1 (en) | Buffered compositions for dialysis | |
| CN104840418A (zh) | 一种盐酸法舒地尔注射液组合物及其制备方法 | |
| JP3672342B2 (ja) | ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル | |
| UA71839C2 (ru) | Фармацевтическая композиция | |
| CN1615906A (zh) | 十八复方氨基酸注射液及其制备方法 | |
| CN108324683A (zh) | 一种稳定的大输液依达拉奉注射液及其制备工艺 | |
| RU2272623C2 (ru) | РАСТВОР ТЕТРАГИДРАТА МОНОНАТРИЕВОЙ СОЛИ N-[O-(п-ПИВАЛОИЛОКСИБЕНЗОЛСУЛЬФОНИЛАМИНО)БЕНЗОИЛ]ГЛИЦИНА И ГОТОВАЯ ЛЕКАРСТВЕННАЯ ФОРМА НА ЕГО ОСНОВЕ | |
| JPH075456B2 (ja) | 点眼液 | |
| JPH07324034A (ja) | フマル酸ケトチフェン含有の点眼剤 | |
| JP4463206B2 (ja) | グリチルリチン高濃度製剤 | |
| CN107789365A (zh) | 多种微量元素ⅴ药物组合物及其用途 | |
| CN110200905A (zh) | 一种盐酸氨溴索组合物及其注射液与应用 | |
| TW436287B (en) | Pharmaceutical composition for intramuscular administration comprising N-substituted benzamides, phenothiazines and their acid addition salts | |
| JPH09124491A (ja) | 重炭酸イオン含有無菌性配合液剤又は製剤及びその製造方法 | |
| JP2003160491A (ja) | ジウリジンリン酸含有点眼液 | |
| CN103638526A (zh) | 一种血液净化用制剂及其制备方法与应用 | |
| CN104721223B (zh) | 一种复方电解质的注射液药物组合物及其制备方法 | |
| RU2483731C1 (ru) | Раствор для инъекций, содержащий налбуфин | |
| JP7217364B2 (ja) | 医薬組成物 | |
| WO2020196381A1 (ja) | 皮下投与用輸液 | |
| WO2024010044A1 (ja) | 眼科組成物 | |
| CN117771174A (zh) | 一种立他司特滴眼液及其制备方法 | |
| JPS6340166B2 (ru) |